NASDAQ · DARE

Dare Bioscience, Inc.

$1.32 +$0.04 (+3.13%) 1D After hours

Key Metrics

$19.17M
Market cap
P/E · TTM
$1.16M
Revenue · TTM
−$12.02M
Net income
EPS · TTM $-1.37
Dividend yield
Free cash flow −$10.16M
Beta · 1Y 0.70
EBITDA · TTM −$9.94M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 22
    From its May 5 high, the share price fell 63%.

    Peak close $3.27 on May 5; trough close $1.22 on Jul 22. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -63%
  • Jul 17
    A material event was filed (Form 8-K).

    8-K - Dare Bioscience, Inc. (0001401914) (Filer)

    RECEIPT: SEC FORM 8-K, TIMESTAMPED
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 4
    The stock moved +32.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 4
  • Apr 16
    The stock moved +52.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 16

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$19.17M
Enterprise value
Shares outstanding15.0M
52-wk range$1.16 – $3.78
Avg volume · 20D216.1K
Net cash
Book value / share$0.08
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Dare Bioscience, Inc.
IPO dateApr 10, 2014
Employees24

Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S16.57
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating -1,034.4%
Net -1,038.8%
FCF -878.3%
ROE / ROIC 455.5% · —

Financial Health

Current ratio1.03
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$540.12K

Cash Flow · TTM

Operating CF −$9.94M
Capex −$227.95K
Free cash flow −$10.16M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

-10.6
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings